Drugs / Lacosamide
Lacosamide
also known as
LCM · SPM 927 · Vimpat · (r)-lacosamide 1 · [R]-2-acetamido-N-benzyl-3-methoxypropionamide · ADD 243037 · Erlosamide · Lacosamida · +9 more
Other / unclassified targets SCN9A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed epilepsy with generalized tonic-clonic seizures 1 milestone | |||||
| Filed | Japan (PMDA) | VIMPAT | epilepsy with generalized tonic-clonic seizures | 2020-02-27 | “a supplemental application for VIMPAT® (generic name: lacosamide) was filed in Japan to expand the indication for adjunctive therapy for tonic-clonic seizures in epilepsy patients” daiichisankyo.com ↗ |
| Filed simple partial epilepsy 1 milestone | |||||
| Filed | Japan (PMDA) | — | simple partial epilepsy | 2015-06-26 | “UCB Japan has applied for marketing authorization for lacosamide in Japan as adjunctive therapy in the treatment of partial onset seizures” daiichisankyo.com ↗ |
| Approved Indication not stated 4 milestones | |||||
| Label expansion | US (FDA) | MOTPOLY XR | — | 2024-06-07 | fda.gov ↗ |
| Label expansions (6) | US (FDA) | VIMPAT | — | 2014-08-29 – 2023-04-28 | fda.gov ↗ |
| Approved | US (FDA) | VIMPAT | — | 2008-10-28 | fda.gov ↗ |
| Approved | EU (EMA) | Vimpat | — | 2008-08-29 | europa.eu ↗ |
Trials 84 · started per year
today
EU approved 2008
US approved 2008
3
3
1
11
1
1
2
4
3
6
6
6
3
7
4
1
2
2
1
1
2
4
4
3
2
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials · 1 met primary | ||||||
| Phase 1 | NCT05788159 | Apr → Jun 2023 | epilepsy | Overseas Pharmaceuticals, Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05603702 | Mar 2023 → Mar 2027 expected | chronic pain syndrome, chronic pancreatitis | Indiana University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03271528 | Apr 2018 → Aug 2020 | alcohol-related disorders | Boston Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01530022 | May 2012 → Jan 2014 | — | UCB Pharma | Completed | Met primary |
| Phase 1 | NCT01530386 | Jan → Jul 2012 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01375387 | Mar → Jun 2011 | — | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01450111 | Nov 2008 → Feb 2009 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01796938 | Jun → Nov 2004 | impaired renal function disease | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03186040 | Jul 2017 → Apr 2020 | amyotrophic lateral sclerosis | Chiba University | Completed | No outcome recorded |
| Phase 220 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04519645 | Mar 2021 → Aug 2024 | neonatal epilepsy syndrome | UCB Biopharma SRL | Terminated | No outcome recorded |
| Phase 2 | NCT03897348 | Sep 2018 → Jun 2019 | alcohol-related disorders | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT02342977 | Nov 2014 → Aug 2016 | avascular necrosis, osteoarthritis, rheumatoid arthritis | Indiana University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01969851 | Feb 2014 → Apr 2018 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01724918 | May 2013 → Aug 2016 | focal epilepsy | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01458522 | May 2012 → Jul 2014 | epilepsy | Aatif Husain | Completed | No outcome recorded |
| Phase 2 | NCT01118962 | Aug 2010 → Oct 2012 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01118949 | May 2010 → Aug 2011 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00938912 | Dec 2009 → May 2021 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00938431 | Nov 2009 → Aug 2014 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00485472 | Mar → Nov 2007 | osteoarthritis, knee | UCB Pharma | Terminated | Missed primary |
| Phase 2 | NCT00440518 | Feb 2007 → Jul 2008 | migraine disorder | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00401830 | Oct 2006 → Feb 2008 | fibromyalgia | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00800215 | Mar → Aug 2004 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00238511 | Nov 2002 → Jan 2005 | postherpetic neuralgia | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00861042 | Apr 2002 → Dec 2004 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00861068 | Feb → Dec 2002 | postherpetic neuralgia | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00552305 | Aug 2001 → Feb 2010 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00861445 | Jun 2001 → Jan 2003 | diabetic polyneuropathy | UCB Pharma | Completed | Met primary |
| Phase 2 | NCT00237458 | May 2001 → Mar 2011 | neuropathy, painful | UCB Pharma | Completed | No outcome recorded |
| Phase 2/34 trials · 1 met primary | ||||||
| Phase 2/3 | NCT02710890 | May 2017 → Jun 2019 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00151879 | Feb 2005 → May 2006 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 2/3 | NCT00235443 | Sep 2004 → Jul 2008 | diabetic neuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 2/3 | NCT00235469 | Apr 2004 → Jun 2005 | diabetic polyneuropathy | UCB Pharma | Completed | Met primary |
| Phase 334 trials · 8 met primary · 3 missed | ||||||
| Phase 3 | NCT07412132 | Jan 2026 → Jan 2027 expected | bipolar disorder | University of Sao Paulo | Recruiting | No outcome recorded |
| Phase 3 | NCT05632133 | Jun 2022 → Aug 2023 | migraine disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05851781 | Jun 2022 → Jul 2023 | migraine disorder | Kafrelsheikh University | Completed | No outcome recorded |
| Phase 3 | NCT05291455 | Mar 2022 → Mar 2024 | epilepsy | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT05626140 | Sep 2021 → May 2022 | sciatica | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT04627285 | Dec 2020 → Feb 2025 | epilepsy | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 3 | NCT02582866 | Jan 2016 → Jan 2020 | epilepsy | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 3 | NCT02408549 | Aug 2015 → Mar 2023 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | Met primary |
| Phase 3 | NCT02477839 | Jun 2015 → May 2020 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | Missed primary |
| Phase 3 | NCT02408523 | Apr 2015 → Apr 2019 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | Met primary |
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT01911975 | Sep 2014 → May 2017 | neuropathy, small fiber | Maastricht University Medical Center | Completed | Met primary |
| Phase 3 | NCT01964560 | Aug 2014 → Apr 2022 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02192814 | Jun → Oct 2014 | focal epilepsy | UCB Japan Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT02124564 | Apr 2014 → Nov 2017 | focal epilepsy | UCB Japan Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01921205 | Aug 2013 → Jan 2017 | epilepsy | UCB Pharma | Completed | Met primary |
| Phase 3 | NCT01832038 | Mar 2013 → Jul 2019 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01710657 | Sep 2012 → Jul 2014 | focal epilepsy | UCB Pharma | Completed | Met primary |
| Phase 3 | NCT01465997 | May 2012 → Jan 2017 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01484977 | Dec 2011 → Dec 2013 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01345058 | Aug 2011 → Feb 2014 | epilepsy | Brigham and Women's Hospital | Completed | Missed primary |
| Phase 3 | NCT01375374 | Jul 2011 → Mar 2013 | focal epilepsy | UCB Pharma | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01243177 | Apr 2011 → Jul 2015 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | Met primary |
| Phase 3 | NCT00655486 | Apr 2008 → Jun 2010 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00655551 | Apr 2008 → Sep 2009 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00530855 | Feb 2008 → Dec 2014 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00220337 | Dec 2004 → Oct 2007 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00515619 | Dec 2004 → Aug 2010 | epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00522275 | Oct 2004 → Oct 2009 | focal epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00135109 | Oct 2004 → Dec 2005 | diabetic neuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00546351 | May 2004 → Jan 2011 | diabetic polyneuropathy | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00220415 | May 2004 → Jan 2006 | focal epilepsy | UCB Pharma | Completed | Met primary |
| Phase 3 | NCT00136019 | Mar 2004 → Aug 2006 | epilepsy | UCB Pharma | Completed | Met primary |
| Phase 3 | NCT00238524 | Dec 2003 → Jan 2005 | diabetic neuropathy | UCB Pharma | Completed | Missed primary |
| Phase 411 trials | ||||||
| Phase 4 | NCT07795593 | Oct 2026 → May 2031 expected | diabetic kidney disease, diabetic neuropathy | University of Michigan | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06866691 | Apr 2025 → Apr 2027 expected | traumatic brain injury | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT06081283 | Nov 2023 → Dec 2024 | brain hypoxia - ischemia, cardiac arrest, intracerebral hemorrhage, traumatic brain injury | University of North Carolina, Chapel Hill | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT05969054 | Jul 2023 → Dec 2025 | Alzheimer disease 3, epilepsy | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase 4 | NCT05598905 | Oct 2022 → Jan 2024 | respiratory underresponsiveness to hypoxia and hypercapnia | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04144218 | Nov 2019 → Oct 2021 | epilepsy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT02409433 | Aug 2014 → Nov 2015 | epilepsy | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01190098 | Aug 2010 → Nov 2014 | focal epilepsy | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01235403 | Jun 2010 → Dec 2011 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase 4 | NCT01175954 | May 2010 → Dec 2015 | epilepsy | Evan Fertig | Completed | No outcome recorded |
| Phase 4 | NCT00955357 | Aug 2009 → Apr 2013 | focal epilepsy | UCB Pharma | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT06969417 | Apr → Jul 2025 overdue | herpes zoster, postherpetic neuralgia | CMH Kharian Medical College | Recruiting | No outcome recorded |
| — | NCT06549426 | Apr 2025 → Dec 2029 expected | epilepsy | University of Twente | Recruiting | No outcome recorded |
| — | NCT01432171 | Jul 2012 → Jun 2017 | malignant glioma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| — | NCT01382017 | Jun 2011 → Aug 2012 | — | University of Kiel | Completed | No outcome recorded |
| — | NCT01110187 | May 2010 → May 2012 | traumatic brain injury | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase not stated1 trial | ||||||
| — | NCT03559673 | — | focal epilepsy | UCB Biopharma S.P.R.L. | No longer available | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 2 | NCT03436433 Comparator | Jan 2019 → Dec 2020 | brain glioma | Duke University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03777956 Comparator | Jan 2019 → Jun 2022 | diabetic neuropathy, neuropathy, painful | Danish Pain Research Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT06243692 Comparator | Feb 2024 → Feb 2025 | migraine disorder | Kafrelsheikh University | Unknown | No outcome recorded |
| Phase 3 | NCT02726867 Comparator | Feb 2014 → Nov 2016 | epilepsy | Mid-Atlantic Epilepsy and Sleep Center, LLC | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01981447 Comparator | Apr 2010 → Aug 2012 | epilepsy | Le Bonheur Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00520741 Comparator | Aug 2007 → Dec 2012 | epilepsy | UCB BIOSCIENCES, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03607851 Comparator | Aug 2018 → Jun 2019 | focal epilepsy | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00832884 Comparator | Mar 2010 → May 2012 | epilepsy | Le Bonheur Children's Hospital | Completed | No outcome recorded |
| — | NCT03636958 Background | Feb 2021 → Jul 2025 | epilepsy | Assistance Publique Hopitaux De Marseille | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2023-12-16 | Zydus Lifesciences Limited | Regulatory Zydus receives final approval from the USFDA for Lacosamide Tablets zyduslife.com ↗
Zydus receives final approval from the USFDA for Lacosamide Tablets |
| 2022-03-21 | Glenmark Pharmaceuticals Ltd. India | Regulatory Glenmark receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg glenmarkpharma.com ↗
The FDA approval for generic Lacosamide Tablets USP reiterates our ongoing commitment to make treatment options more accessible for patients. |
| 2022-03-01 | Alembic Pharmaceuticals Ltd. | Regulatory 21st March, 2022, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg. |
| 2022-02-02 | UCB Pharma | Regulatory UCB Receives Positive CHMP Opinion Recommending Approval of BRIVIACT[®] (brivaracetam) and VIMPAT[®] (lacosamide) in the EU for Partial-Onset Seizures in Pediatric Patients From Two to Four Years ucb.com ↗ |
| 2020-02-27 | Daiichi Sankyo | Regulatory Anti-epilepsy Drug VIMPAT ®, Submission for Supplemental Application for Approval in Japan daiichisankyo.com ↗ |
| 2019-01-08 | Daiichi Sankyo | Regulatory Pediatric Dosage and Administration Approved for Anti-epileptic Drug VIMPAT® Tablets 50 mg and 100 mg daiichisankyo.com ↗
VIMPAT® Tablets 50 mg and 100 mg (generic name: lacosamide) has been approved, adding a new dosage and administration regimen for pediatric patients (4 years and older) |
| 2017-09-01 | Daiichi Sankyo | Regulatory Restriction on prescription period lifted for antiepileptic VIMPAT® Tablets 50 mg and 100 mg daiichisankyo.com ↗
Daiichi Sankyo Company, Limited (headquarters: Chuo-ku, Tokyo; hereafter referred to as “Daiichi Sankyo”) and UCB Japan Co., Ltd. (headquarters: Shinjuku-ku, Tokyo; hereafter referred to as “UCB Japan”; when referring to the global UCB group, “UCB” ) are pleased to announce today that the Ministry of Health, Labor and Welfare issued a notification announcing the lifting of “the 14-day restriction on the prescription period” for the antiepileptic VIMPAT® Tablets 50 mg and 100 mg (generic name: lacosamide). |
| 2017-08-25 | Daiichi Sankyo | Regulatory Antiepileptic VIMPAT® Tablets 50 mg and 100 mg approved for monotherapy for Partial-onset Seizures in Epilepsy Patients daiichisankyo.com ↗
It had already been approved for partial-onset seizure (including secondary generalized seizures) in adult patients with epilepsy in combination with other agents, as a result of partial amendment of approval, today VIMPAT® was approved for monotherapy. |
| 2016-08-26 | Daiichi Sankyo | Regulatory Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan daiichisankyo.com ↗
Antiepileptic lacosamide filed for partial amendment of approval to add a new indication in Japan |
| 2016-07-04 | Daiichi Sankyo | Regulatory UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT®) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy daiichisankyo.com ↗
Daiichi Sankyo Company, Limited ("Daiichi Sankyo"; TSE: 4568) and UCB Biopharma SPRL ("UCB") today announced the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted approval for lacosamide (brand name VIMPAT®) as an adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in adult patients with epilepsy who have not obtained sufficient response to other antiepileptic drugs. |
| 2015-12-21 | Daiichi Sankyo | Results Results of Analysis of Data from Clinical Trial of Lacosamide (Generic Name) Announced at 2015 Annual Meeting of the American Epilepsy Society daiichisankyo.com ↗
The study met its primary endpoint for the change in POS frequency per 28 days from baseline to maintenance in the lacosamide 200 mg/day and 400 mg/day. |
| 2015-06-26 | Daiichi Sankyo | Regulatory Application for Marketing Authorization for Lacosamide (Generic Name) in Japan for the Treatment of Epilepsy daiichisankyo.com ↗
UCB Japan has applied for marketing authorization for lacosamide in Japan as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalization in patients who have not obtained sufficient response to other antiepileptic drugs. |
All press releases naming this drug 18 releases
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 99 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lacosamide | “Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin,...” NCT03636958 ↗90“This phase 3 trial is being conducted at approximately 80 sites in the United States (U.S.) to investigate whether lacosamide (SPM 927) at different doses reduces pain in...” NCT00135109 ↗ “The purpose of the study is to evaluate the effectiveness, safety and tolerability of consistent dosages of a study drug (lacosamide [SPM 927]) taken orally twice a day for...” NCT00136019 ↗ “This phase 2b trial is being conducted at approximately 60 sites in the US to investigate whether lacosamide (SPM 927) at different doses reduces pain in subjects with diabetic...” NCT00235469 ↗ “The purpose of this study is to evaluate the effectiveness, safety and tolerability of consistent dosages of study drug (lacosamide) taken orally twice a day for about 4 months.” NCT00220415 ↗ “Lacosamide is a new antiepileptic drug effective for adjunctive treatment of partial-onset seizures.” PMID 20041945 ↗ Dec 2009 “400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy” NCT00238524 ↗ “a first parenteral anti-seizure medication (levetiracetam, valproate, or lacosamide)” NCT06549426 ↗ “Sodium Channel Blockers: Oxcarbazepine, Lamotrigine, Lacosamide” NCT07795593 ↗ “long-term administration of Lacosamide” NCT00238511 ↗ |
| Known as | (r)-lacosamide 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | [R]-2-acetamido-N-benzyl-3-methoxypropionamide | “Lacosamide ([R]-2-acetamido-N-benzyl-3-methoxypropionamide) belongs to a novel class of functionalized amino acids.” NCT01190098 ↗ |
| Known as | ADD 243037 | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Erlosamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide adroiq | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide cv | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Lacosamide extended release tablets | “Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage...” NCT05788159 ↗ |
| Known as | Lacosamide Tablets | “Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than...” NCT05788159 ↗ |
| Known as | Lacosamide ucb | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | LCM | “The primary objective of this Phase 1 crossover study is to evaluate the neuropsychological effects of Lacosamide (LCM) compared to Carbamazepine Immediate Release (CBZ-IR)...” NCT01530022 ↗7“continued access to Lacosamide (LCM) for monotherapy use” NCT03559673 ↗ “lacosamide (LCM) added to levetiracetam (LEV)” PMID 27714769 ↗ Oct 2016 “Strength: Lacosamide (LCM) 50 mg, LCM 100 mg” NCT01832038 ↗ “start dose Lacosamide (LCM) is 100 mg/day” NCT01375374 ↗ “Lacosamide (LCM)” NCT01243177 ↗ “lacosamide (LCM)” NCT01382017 ↗ |
| Known as | Motpoly | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | Motpoly xr | ChEMBL registry synonym — accepted as the source's own label CHEMBL58323 ↗ |
| Known as | SPM 927 | “Each patient who qualifies and chooses to participate in the study will receive placebo (inactive drug) or gradually increasing doses of lacosamide (SPM 927) up to the target...” NCT00220415 ↗6“The purpose of the study is to evaluate the effectiveness, safety and tolerability of consistent dosages of a study drug (lacosamide [SPM 927]) taken orally twice a day for...” NCT00136019 ↗ “400mg/Day and 600mg/Day SPM 927 (Lacosamide) in Subjects With Painful Distal Diabetic Neuropathy” NCT00238524 ↗ “Oral SPM 927” NCT00238511 ↗ |
| Known as | SPM927 / Lacosamide / Vimpat | “SPM927 / Lacosamide / Vimpat®” NCT00861042 ↗ |
| Known as | Vimpat | “The purpose of this study is to investigate the impact of the anti-seizure medication Lacosamide (Vimpat®) on sleep and wakefulness in adults with focal (partial onset) seizures.” NCT01190098 ↗3“INTERVENTION: Four- to six-week Titration Phase followed by 12-week maintenance treatment with adjunctive lacosamide (Vimpat®) [200, 400 or 600 mg/day] or placebo.” PMID 21090839 ↗ Dec 2010 “Lacosamide, Vimpat®” NCT00861068 ↗ “Lacosamide, Vimpat®” NCT00861445 ↗ |
| Action | Inhibit | “This mechanism of action results in stabilization of hyperexcitable neuronal membranes, inhibition of neuronal firing, and reduction in long-term channel availability without...” PMID 23859801 ↗ Jul 2013 |
| Modality | Other / unclassified | “belongs to a novel class of functionalized amino acids.” NCT01190098 ↗ |
| Route | Oral | “The efficacy and tolerability of oral lacosamide (200, 400, and 600 mg/day) was evaluated in patients with painful diabetic neuropathy” PMID 19409861 ↗ May 2009 |
| Target | SCN9A | “The finding of voltage-gated sodium channel mutations in small fibre neuropathy (with mutations in SCN9A, encoding for Nav1.7) being most frequently reported suggest a specific...” PMID 30649227 ↗ Feb 2019 |